| scholarly article | Q13442814 |
| P2093 | author name string | Jürgen Sonnemann | |
| James F. Beck | |||
| Chithra D. Palani | |||
| P2860 | cites work | Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX | Q24294074 |
| Acetylation is indispensable for p53 activation | Q24313477 | ||
| Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy | Q24651380 | ||
| A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 | Q24657532 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Analyzing real-time PCR data by the comparative C(T) method | Q28131831 | ||
| Deacetylation of p53 modulates its effect on cell growth and apoptosis | Q28138967 | ||
| Hdmx modulates the outcome of p53 activation in human tumor cells | Q28257444 | ||
| The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species | Q28349324 | ||
| Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 | Q28377610 | ||
| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations | Q29614275 | ||
| Modes of p53 regulation | Q29615657 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| p53 in health and disease | Q29619939 | ||
| Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment | Q33533630 | ||
| Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy | Q34478557 | ||
| Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). | Q34520098 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Awakening guardian angels: drugging the p53 pathway | Q35014385 | ||
| Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma | Q35808910 | ||
| Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib | Q36902184 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? | Q37068706 | ||
| Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? | Q37252722 | ||
| Development of vorinostat: current applications and future perspectives for cancer therapy | Q37381104 | ||
| HDACi--targets beyond chromatin. | Q37430947 | ||
| HDAC inhibitor-based therapies and haematological malignancy | Q37514642 | ||
| Romidepsin for the treatment of cutaneous T-cell lymphoma | Q37686109 | ||
| Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. | Q40032210 | ||
| Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells | Q40039773 | ||
| Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells | Q40132729 | ||
| Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity | Q40149346 | ||
| Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy | Q40213156 | ||
| MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. | Q40244145 | ||
| MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. | Q40324423 | ||
| Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. | Q40604095 | ||
| Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line | Q41092576 | ||
| Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines | Q41520126 | ||
| Inactivation of the p53 pathway in retinoblastoma. | Q42152329 | ||
| Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. | Q42445479 | ||
| Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway | Q43186270 | ||
| MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death | Q45862563 | ||
| Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3 | Q58664384 | ||
| Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway | Q58862256 | ||
| Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors | Q81489492 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 25-36 | |
| P577 | publication date | 2010-08-03 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression | |
| P478 | volume | 30 |
| Q41923624 | Bone sarcomas: from biology to targeted therapies. |
| Q38129954 | Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? |
| Q39366270 | Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress |
| Q42427815 | Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling |
| Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
| Q38997002 | MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways |
| Q38989476 | Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia |
| Q35200108 | PAI-1 Expression Is Required for HDACi-Induced Proliferative Arrest in ras-Transformed Renal Epithelial Cells |
| Q39446764 | Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. |
| Q38178277 | Targeted therapies for bone sarcomas |
| Q38247168 | Targeting p53-MDM2-MDMX loop for cancer therapy |
| Q35783751 | Towards an understanding of the role of p53 in adrenocortical carcinogenesis |
| Q37558978 | p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. |
Search more.